Fig. 7
Cisplatin promoted apoptosis by promoting RUNX1 expression in NB cells. a SH-SY5Y cells were treated with cytarabine (0, 2, 4, 6 and 8 μM) and cisplatin (0, 20, 40, 60 and 80 μM) for 24 h, the number of viable SH-SY5Y was analysed using CCK8 assay. b Cell counting kit-8 assay depicting the change in cell viability of SH-SY5Y cells under different time (0, 12, 24, 36, 48, 60, 72 h) of cytarabine and cisplatin treatment. c Western blot assays indicating the RUNX1 levels (normalized to β-actin, n = 5) in SH-SY5Y cells treated with DMSO, cytarabine and cisplatin at indicated time points. *p < 0.05 vs. DMSO. d Western blot assays (left panel) and the ratio of Bcl-2/Bax (right panel) showing the protein levels of RUNX1, Bax, Bcl-2, and cleaved caspase-3 in SH-SY5Y cells stably transfected with sh-Scb or sh-RUNX1#1, and those treated with cisplatin and DMSO for 48 h. e Representative images (left panel) and quantification (right panel) of flow cytometry showing the apoptosis of SH-SY5Y cells stably transfected with sh-Scb or sh-RUNX1 and treated with DMSO or cisplatin. Cells were double stained with an FITC-conjugated anti-Annexin V antibody and PI. The cells in the upper right and lower right quadrants depict late and early apoptosis. f Representative images (left panel) and quantification (right panel) of the mitochondrial membrane potential were evaluated with JC-1 (2 μg/ml) dye of SH-SY5Y cells stably transfected with sh-Scb or sh-RUNX1 and treated with DMSO or cisplatin. Scale bar, 100 μm. **P < 0.01 vs. sh-Scb + DMSO, ***P < 0.001 vs. sh-Scb + DMSO. Data are shown as mean ± SEM and representative of three independent experiments in panels (a)–(f). Data information: Data are presented as mean ± SEM. Exact P values are specified in Additional file 2: Table S3